• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:03:56 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LCI alert in real time by email
    SC 13G/A 1 tm215909d15_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 4)

     

    Under the Securities Exchange Act of 1934

     

     

    Lannett Company, Inc.

    (Name of Issuer)

     

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

     

    516012101

    (CUSIP Number)

     

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the following box to designate the rule pursuant to which the Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 516012101

     

      1.

    Names of Reporting Persons

    I.R.S. Identification Nos. of above persons (entities only)

    D. E. Shaw & Co., L.P.

    13-3695715

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) [     ]
       

    (b)

     

    [     ]
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    1,860,006

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    1,887,047

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,887,047

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [     ]

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.5%

     

      12.

    Type of Reporting Person (See Instructions)

    IA, PN

      

     

     

     

    CUSIP No. 516012101

     

      1.

    Names of Reporting Persons

    I.R.S. Identification Nos. of above persons (entities only)

    David E. Shaw

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) [     ]
       

    (b)

     

    [     ]
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    1,860,006

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    1,887,047

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,887,047

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [     ]

     

      11.

    Percent of Class Represented by Amount in Row (9)

    4.5%

     

      12.

    Type of Reporting Person (See Instructions)

    IN

     

     

     

     

    Item 1.
      (a) Name of Issuer
       

    Lannett Company, Inc.

       
      (b) Address of Issuer's Principal Executive Offices
       

    9000 State Road

    Philadelphia, PA 19136

       
    Item 2.
      (a) Name of Person Filing
       

    D. E. Shaw & Co., L.P.

    David E. Shaw

       
      (b) Address of Principal Business Office or, if none, Residence
       

    The business address for each reporting person is:

    1166 Avenue of the Americas, 9th Floor

    New York, NY 10036

       
      (c) Citizenship
       

    D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.

    David E. Shaw is a citizen of the United States of America.

       
      (d) Title of Class of Securities
       

    Common Stock, $0.001 par value

       
      (e) CUSIP Number
       

    516012101

       
    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable

     

    Item 4.

    Ownership

     

    As of December 31, 2020:

     

    (a)Amount beneficially owned:

     

     

    D. E. Shaw & Co., L.P.:

    1,887,047 shares

    This is composed of (i) 889,930 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (ii) 194,209 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (iii) 1,120 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 801,788 shares under the management of D. E. Shaw Investment Management, L.L.C.

     

     

    David E. Shaw:

    1,887,047 shares

    This is composed of (i) 889,930 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (ii) 194,209 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (iii) 1,120 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 801,788 shares under the management of D. E. Shaw Investment Management, L.L.C.

     

     

     

     

    (b)Percent of class:
      D. E. Shaw & Co., L.P.:

    4.5%

      David E. Shaw:

    4.5%


    (c)Number of shares to which the person has:
    (i)Sole power to vote or to direct the vote:
      D. E. Shaw & Co., L.P.: -0- shares
      David E. Shaw: -0- shares   

     

    (ii)Shared power to vote or to direct the vote:

      D. E. Shaw & Co., L.P.:

    1,860,006 shares

      David E. Shaw:

    1,860,006 shares

     

    (iii)Sole power to dispose or to direct the disposition of:
      D. E. Shaw & Co., L.P.: -0- shares   
      David E. Shaw: -0- shares   

     

    (iv)Shared power to dispose or to direct the disposition of:

      D. E. Shaw & Co., L.P.:

    1,887,047 shares

      David E. Shaw:

    1,887,047 shares

     

    David E. Shaw does not own any shares directly. By virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C. and D. E. Shaw Adviser, L.L.C., which in turn is the investment adviser of D. E. Shaw Asymptote Portfolios, L.L.C., and by virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Manager, L.L.C., which in turn is the manager of D. E. Shaw Asymptote Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 1,860,006 shares, and the shared power to dispose or direct the disposition of 1,887,047 shares, the 1,887,047 shares as described above constituting 4.5% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 1,887,047 shares.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

    Not Applicable

     

    Item 10. Certification

    By signing below, each of D. E. Shaw & Co., L.P. and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. A Power of Attorney, dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, is attached hereto.

     

    Dated: February 16, 2021

     

      D. E. Shaw & Co., L.P.
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Chief Compliance Officer

      

     

      David E. Shaw
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Attorney-in-Fact for David E. Shaw

     

     

     

    Get the next $LCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LCI

    DatePrice TargetRatingAnalyst
    8/31/2021$7.00 → $6.00Neutral
    Roth Capital
    More analyst ratings

    $LCI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT SHARES UPDATE

    Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

    4/4/23 6:55:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    SEC Filings

    View All

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:08 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:20 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:14 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Chapman John C bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 13% to 174,324 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/18/22 4:09:03 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Lepore Patrick G bought $49,000 worth of shares (100,000 units at $0.49), increasing direct ownership by 21% to 587,145 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:16:01 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Crew Timothy C bought $7,200 worth of shares (15,000 units at $0.48), increasing direct ownership by 3% to 604,291 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:14:53 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $6.00 from $7.00 previously

    8/31/21 8:50:46 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $7.00 from $7.50 previously

    6/10/21 9:57:43 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Financials

    Live finance-specific insights

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

    TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a

    1/25/23 6:52:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/10/23 9:46:33 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    6/3/22 1:48:32 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/11/22 8:19:58 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care